Literature DB >> 3886850

Efficacy of chymopapain chemonucleolysis. A long-term review of 105 patients.

M J Javid.   

Abstract

A 9- to 12-year follow-up review was conducted in 105 of 124 patients who were treated with chymopapain chemonucleolysis for herniated lumbar disc. The data were obtained from responses to a questionnaire. Seventy-nine patients (75.2%) reported marked improvement, six (5.7%) had slight improvement, and 20 (19.0%) had no improvement. Of the 87 patients not receiving workman's compensation, 70 patients (80.5%) had marked improvement; four (4.6%) had slight improvement; and 13 (14.9%) had no improvement. Of the 18 compensation cases, nine patients (50.0%) had marked improvement; two patients (11.1%) had slight improvement; and seven patients (38.9%) had no improvement. These results are comparable to those reported for surgical discectomy, and confirm that chymopapain chemonucleolysis is an alternative to surgery.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3886850     DOI: 10.3171/jns.1985.62.5.0662

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  4 in total

1.  Chemonucleolysis versus surgical discectomy for sciatica secondary to lumbar disc herniation. A cost and quality-of-life evaluation.

Authors:  R Launois; B Henry; J R Marty; M Gersberg; C Lassale; M Benoist; J M Goehrs
Journal:  Pharmacoeconomics       Date:  1994-11       Impact factor: 4.981

2.  The results of "lumbar disc surgery" following unsuccessful chemonucleolysis.

Authors:  M Brock; L Pedretti; H M Mayer
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

3.  Sciatica caused by disc herniation: Why is Chymopapain Chemonucleolysis denied to our patients?

Authors:  Douglas Wardlaw
Journal:  Int J Spine Surg       Date:  2016-12-31

4.  Chemonucleolysis of lumbar intervertebral disc prolapse with chymopapain: outcome after 1 year.

Authors:  K A Grindulis; D B Finlay; F E Nichol
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.